<DOC>
	<DOCNO>NCT03047603</DOCNO>
	<brief_summary>The incidence Hepatocellular carcinoma ( HCC ) increase worldwide . However , HCC case advance stage diagnosis established.Early diagnosis improve prognosis.The study intend evaluate diagnostic efficiency Protein Induced Vitamin K Absence antagonist-II ( PIVKA-II ) . This study international multicenter study join several hospital China , Singapore , Thailand Vietnam . Participants include healthy control , HCC , metastatic liver cancer , Hepatitis B virus ( HBV ) liver cirrhosis consecutively recruit cohort . All serum sample collect treatment test single center order decrease bias . Serum sample test PIVKA-II , alpha-fetoprotein biochemical index include alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , gamma-glutamyl transferase ( GGT ) , alpha-l-fucosidase ( AFU ) , etc .</brief_summary>
	<brief_title>Evaluation Diagnostic Efficiency PIVKA-II Other Tumor Markers HCC</brief_title>
	<detailed_description>Hepatocellular carcinoma ( HCC ) third leading cause cancer death worldwide.Early diagnosis improves prognosis . Protein induce vitamin K antagonist-II ( PIVKA-II ) , also know des-γ-carboxyprothrombin ( DCP ) acarboxy prothrombin , abnormal form prothrombin induce vitamin K absence antagonist-II . The study intend evaluate diagnostic efficiency Protein Induced Vitamin K Absence antagonist-II ( PIVKA-II ) . PIVKA-II effective tumor marker hepatocellular carcinoma ( HCC ) widely use western country case hepatitis C virus ( HCV ) related.However , majority HCCs China HBV relate . Despite extensive application PIVKA-II hospital China , diagnostic efficiency include sensitivity , specificity , positive predictive value negative predictive value still need clinical data evaluate . The research purpose list follows：1.Determination diagnostic Cut-off value 2.Evaluation diagnostic efficiency PIVKA-II 3.Evaluation combination PIVKA-II tumor marker HCC . This study international multicenter study join several hospital China , Singapore , Thailand Vietnam . Participants include healthy control , HCC , metastatic liver cancer , HBV liver cirrhosis consecutively recruit cohort . All serum sample collect treatment test single center order decrease bias . Serum sample test PIVKA-II , Alpha-fetoprotein ( AFP ) ，alpha-fetoprotein L3 biochemical index include ALT , AST , GGT , AFU , etc . The diagnosis HCC base histopathology . All HCC diagnosis confirm time analysis.The Student 's t-test ( Mann-Whitney test ) use compare continuous variable , chi-square test ( Fisher 's exact test ) use categorical variable . A receiver operator characteristic ( ROC ) curve use assess performance characteristic PIVKA-II , AFP , AFP-L3 measurement .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Age 18 85 Receiving treatment diagnosis Establishing Diagnosis accord Asian Pacific Association Study Liver ( APASL ) criteria Clinical data miss Laboratory test information miss Serum sample n't qualify Obstructive jaundice patient Medical history take warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Protein induce vitamin K absence antagonist-II</keyword>
	<keyword>Differential diagnosis</keyword>
	<keyword>Des-γ-carboxy prothrombin</keyword>
	<keyword>Alpha-fetoprotein</keyword>
	<keyword>Lens culinaris agglutinin-reactive fraction alpha-fetoprotein-fetoprotein</keyword>
</DOC>